roches

FDA approves Roches Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…

2 months ago

Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)

July 22, 2025 12:45 ET  | Source: F. Hoffmann-La Roche Ltd Participation certificates (Partizipationsscheine) with a nominal value of CHF…

5 months ago